Acamprosate Does Not Require Titration
Acamprosate is initiated at full therapeutic dose without titration—there is no gradual dose escalation required. 1
Standard Dosing Protocol
For patients with normal renal function, start acamprosate at the full dose of 666 mg (two 333 mg tablets) three times daily immediately upon initiation. 1 This differs fundamentally from many other psychotropic medications that require gradual titration.
Weight-Based Dosing
- Patients ≥60 kg: 666 mg three times daily (1998 mg/day total) 2, 1
- Patients <60 kg: Reduce dose by one-third to 1332 mg/day 2, 3
Renal Impairment Dosing
- Moderate renal impairment (CrCl 30-50 mL/min): Start at reduced dose of 333 mg three times daily 1
- Severe renal impairment (CrCl ≤30 mL/min): Contraindicated 1
Critical Timing Considerations
Acamprosate must be initiated 3-7 days after the last alcohol consumption, only after withdrawal symptoms have completely resolved—not immediately after sobering up. 2, 3, 1 This timing is essential because:
- Acamprosate is effective for maintaining abstinence rather than inducing it 2, 3
- The drug does not treat acute withdrawal symptoms 2
- Starting too early (before complete detoxification) reduces efficacy 3
Pharmacokinetic Rationale for No Titration
The lack of titration requirement is supported by acamprosate's unique pharmacokinetic profile:
- Steady-state is reached within 5-7 days at the full therapeutic dose 2, 1, 4
- The drug is not metabolized and has no protein binding 1, 4
- Acamprosate demonstrates time- and dose-independent pharmacokinetics 4
- There is no hepatotoxicity risk, making it particularly safe even at full dose initiation 2
Common Pitfalls to Avoid
Do not attempt to "titrate up" acamprosate as you would with gabapentin, antidepressants, or other CNS medications. 1 Key mistakes include:
- Starting at subtherapeutic doses: The full dose is required for efficacy; lower doses may not maintain abstinence 1, 5
- Initiating too early: Starting before withdrawal resolution (3-7 day window) compromises effectiveness 2, 3
- Failing to combine with psychosocial support: Acamprosate should always be part of comprehensive treatment 3, 1
- Premature discontinuation: Treatment should continue for at least 3-6 months, potentially up to 12 months 2, 3
Safety Profile at Full Dose
Acamprosate is well-tolerated when started at full therapeutic dose, with primarily mild gastrointestinal side effects. 6, 5 The most common adverse event is diarrhea (16% vs 10% placebo), which is typically transient and does not require dose reduction or discontinuation 6. Discontinuation rates due to adverse events are comparable to placebo 6, 5.
Treatment Duration
Continue acamprosate for a minimum of 3-6 months, with potential extension to 12 months for optimal outcomes. 2, 3 Clinical trials demonstrating superior abstinence rates (38% vs 25% placebo) were based on sustained treatment over these longer periods 7, 2.